Northwest Biotherapeutics, Inc.
NWBO
$0.21
-$0.004-1.87%
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -12.07% | 153.73% | -67.73% | -25.46% | 97.09% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -12.07% | 153.73% | -67.73% | -25.46% | 97.09% |
| Cost of Revenue | 12.90% | 33.46% | 15.76% | -20.30% | -6.41% |
| Gross Profit | -14.39% | -29.44% | -28.04% | 19.94% | 9.25% |
| SG&A Expenses | -0.03% | 27.99% | 15.80% | -13.69% | -13.53% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 6.51% | 30.45% | 15.78% | -16.98% | -10.07% |
| Operating Income | -7.06% | -28.63% | -21.44% | 16.70% | 11.48% |
| Income Before Tax | 17.63% | -23.68% | -71.91% | 33.14% | 28.40% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 17.63% | -23.68% | -71.91% | 33.14% | 28.40% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 17.63% | -23.68% | -71.91% | 33.14% | 28.40% |
| EBIT | -7.06% | -28.63% | -21.44% | 16.70% | 11.48% |
| EBITDA | -7.06% | -28.75% | -21.28% | 17.59% | 12.41% |
| EPS Basic | 26.89% | -11.85% | -54.37% | 37.83% | 32.91% |
| Normalized Basic EPS | 16.13% | -8.86% | -57.41% | 38.82% | 52.31% |
| EPS Diluted | 5.66% | -48.15% | -94.17% | 25.84% | 32.91% |
| Normalized Diluted EPS | 16.13% | -8.86% | -57.41% | 38.82% | 52.31% |
| Average Basic Shares Outstanding | 10.95% | 9.55% | 10.54% | 9.46% | 8.97% |
| Average Diluted Shares Outstanding | 10.95% | 9.55% | 10.54% | 9.46% | 8.97% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
